Endo International Plunges, as the Valeant Cancer Spreads

The entire biotech industry is being dismantled today, under the dark clouds of Valeant Pharmaceuticals. The two largest drops in the sector, outside of VRX, are MNK and ENDP. The common denominator is all three companies have pursued a grow by acquisition strategy, one that entailed jacking up the price of drugs to improve margins.

This has proven to be a disastrous model during this politically charged business cycle.

Perhaps these stocks rebound, wildly, after H. Clinton becomes the first female President of the United States. After all, the healthcare lobbyists will not permit her to take malevolent actions against their clients. Since she’s a team player and part of the status quo, it’s very likely that a H. Clinton win could equate to a gargantuan rally in all of these stocks that her rhetoric has helped destroy in the first place.

Alas, the joys of politicians and their empty promises.